VERACYTE, INC.VCYTEarnings & Financial Report
Nasdaq · Health Care · Services-Medical Laboratories
Veracyte Inc. is a leading molecular diagnostics company that develops and commercializes proprietary genomic testing solutions for early, accurate detection of cancer and other complex diseases. Its offerings help healthcare providers make better clinical decisions to improve patient outcomes, with core operations in the U.S. and expanding global market presence across key clinical segments.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| ARK | 10.48% | 7.7M | — | 2024-01-29 |
| BlackRock, Inc. | 10.20% | 7.8M | ▲ +0.40pp | 2024-07-08 |
| The Vanguard Group | 10.08% | 7.7M | ▲ +0.33pp | 2024-10-02 |
| Artisan Partners Limited Partnership | 6.50% | 5.0M | ▲ +2.10pp | 2024-11-12 |
| Wellington Management Group LLP | 5.51% | 4.2M | ▼ -4.17pp | 2024-11-08 |
| STATE STREET CORPORATION | 4.26% | 92.3K | — | 2024-01-22 |
Insider Transactions
Net 90d: −$3.21M · buys $0 / sells $3.21MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-10 | Haas Kevin Richard | Chief Dev and Tech Officer | Grant | 44.2K | $0.00 | $0 |
| 2026-03-06 | John Leite | Chief Commercial Officer-CLIA | Grant | 36.2K | $0.00 | $0 |
| 2026-03-06 | John Leite | Chief Commercial Officer-CLIA | Grant | 6.6K | $0.00 | $0 |
| 2026-03-06 | Febbo Phillip G. | Chief Scientific & Med Officer | Grant | 29.6K | $0.00 | $0 |
| 2026-03-06 | Febbo Phillip G. | Chief Scientific & Med Officer | Grant | 6.6K | $0.00 | $0 |
| 2026-03-06 | McGuire Annie | SVP, General Counsel | Grant | 32.9K | $0.00 | $0 |
| 2026-03-06 | McGuire Annie | SVP, General Counsel | Grant | 26.3K | $0.00 | $0 |
| 2026-03-06 | Rebecca Chambers | Chief Financial Officer | Grant | 36.2K | $0.00 | $0 |
| 2026-03-06 | Rebecca Chambers | Chief Financial Officer | Grant | 13.2K | $0.00 | $0 |
| 2026-03-06 | Jonathan Wygant | VP, Chief Accounting Officer | Grant | 10.5K | $0.00 | $0 |
1–10 of 24
Page 1 / 3